262-513-0700

IPC Research

What if we could slow your loved one's ALZHEIMER'S with better sleep?

The ReCOGNITION study staff is always available to answer any questions or concerns about the study or the study drugs.

  • Review of medical history (including past and current health, medications, or treatments)
  • Physical exams
  • Vital signs measurements
  • Reviews of current medications
  • Blood and urine sample collections
  • ​Tests that measure mental skills and memory
  • ​Reviews of study drug use
  • ​Reviews of any side effects experienced

What will happen during the ReCOGNITION study?

For additional information, call Anne at IPC Research, 262-513-0700.


If you or someone you care about has been diagnosed with mild Alzheimer's, learn more about the ReCOGNITION study evaluating an investigational sleep-promoting Alzheimer's disease drug.

What if I have questions?

To pre-qualify for this study, a patient must:

Mild ​Alzheimers Study​

All study-related visits, tests, and drugs will be provided to eligible participants at no cost. In addition, reimbursement for study-related time and travel may be provided.

  • Be 60 to 85 years of age
  • Be diagnosed with mild dementia due to Alzheimer's disease and experienced a cognitive decline over at least 6 months
  • Not have an alternative cause for dementia other than Alzheimer's disease
  • Have a permanent caregiver, who stays under the same roof at least 3 nights a week

Who is eligible to participate in the ReCOGNITION study?

Before a patient can begin the study, he or she will be screened for eligibility. If the patient is determined to be eligible, and agrees to participate, he or she will be randomly assigned (like the flip of a coin) to receive one of three doses (5 mg, 20 mg, or 50 mg) of the investigational drug, or placebo. Study participants have a greater chance of receiving the investigational drug than placebo.

Study participants, the study doctor, and study staff members will not know which study drug (investigational or placebo) participants are receiving. This is to prevent any opinions about the investigational drug or placebo from affecting the results of the study. However, in the event of an emergency, this information will be provided.

Study participants will take their study drug once daily following a meal or snack, preferably between 9 pm and 11 pm. Participants will be asked to take their study drug for 26 weeks and visit the study clinic 5 times during the study. Participants will also receive weekly telephone calls from the study staff. Total study participation will last approximately 28 weeks.

Throughout the study, doctors and the study staff will evaluate the health and progress of all study participants through various tests and assessments during the clinic visits and weekly phone calls. Some of these include, but are not limited to: